Evidence map›Paper›PMID 39991182›Full record

ArticleNeuro-oncology advances

A multi-institutional retrospective cohort of adult-onset medulloblastoma in the modern era.

Alipi V Bonm, Michael S Rutenberg, Kate E Therkelsen, John Herbst, Anurag Sanaf, Marissa A Sherwood, John Y Rhee, Tresa M McGranahan, Patrick J Cimino, L Nicolas Gonzalez Castro and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alipi V BonmBen and Catherine Ivy Center for Advanced Brain Tumor Treatment, Swedish Neuroscience Institute, Seattle, Washington, USA.ORCID https://orcid.org/0009-0005-6637-0279
Michael S RutenbergDepartment of Radiation Oncology, Mayo Clinic, Jacksonville, Florida, USA.
Kate E TherkelsenDepartment of Neurology, Stanford University, Stanford, California, USA.
John HerbstDepartment of Medical Oncology, Allegheny Health Network Cancer Institute, Pittsburgh, Pennsylvania, USA.
Anurag SanafDepartment of Radiation Oncology, Dana Farber Cancer Institute, Boston, Massachusetts, USA.
Marissa A SherwoodRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
John Y RheeDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston Massachusetts, USA.
Tresa M McGranahanDepartment of Neurology, Scripps Medical Center, Encinitas, California, USA.
Patrick J CiminoNeuropathology Unit, Division of Intramural Research, National Institutes of Health, Bethesda, Maryland, USA.
L Nicolas Gonzalez CastroDepartment of Neurology, Brigham and Women's Hospital, Harvard Medical School, Boston Massachusetts, USA.
Derek S TsangRadiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Matthias A KarajannisDepartment of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
Seema NagpalDepartment of Neurology, Stanford University, Stanford, California, USA.ORCID https://orcid.org/0000-0002-0289-2319
Robert J AmdurDepartment of Radiation Oncology, University of Florida, Gainesville, Florida, USA.
Helen ShihDepartment of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Jason BarberDepartment of Neurological Surgery, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0002-3016-7800
Lynne P TaylorDepartments of Neurology and Neurosurgery, Alvord Brain Tumor Center, University of Washington, Seattle, Washington, USA.ORCID https://orcid.org/0000-0001-5946-3796

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Elisa de Stanchina · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Background: Adult onset medulloblastoma (aMB) is a rare tumor with limited available evidence. We present a large multi-institutional retrospective cohort of aMB patients treated in the modern era, with an emphasis on understanding the role of chemotherapy at initial diagnosis. Methods: We included 267 consecutive patients with aMB treated at 7 different institutions from 2000-present, controlling for chemotherapy regimen and cycles received. Results: Treatment factors were highly intercorrelated with one another and with treating institution. Concurrent chemotherapy was not associated with overall survival (OS). Adjuvant chemotherapy was associated with OS on univariable analyses (HR = 0.55, Conclusions: There was no benefit of concurrent chemotherapy. Adjuvant chemotherapy was associated with improved overall survival and this effect was driven by select subgroups, specifically those with M0 disease and those with residual tumor. We could not confirm that these associations are independent of the treating institution.

Indexed as

adjuvant chemotherapyadult medulloblastomaconcurrent chemotherapycraniospinal radiationproton

Identifiers

PMID39991182
PMCPMC11842969

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.